Last reviewed · How we verify
NCT06373094
A Single Dose Escalation Study of HHT201 in Healthy Subjects
Phase 1 trial testing Donepezil Dihydroxynaphthalate for Injection in Alzheimer Disease in 64 participants. Not yet recruiting.
31 March 2025
Quick facts
| Lead sponsor | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 1 June 2024 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Donepezil Dihydroxynaphthalate for Injection — full drug profile →
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
Shanghai Synergy Pharmaceutical Sciences Co., Ltd. — full company profile →
Who can join
Adults 20 to 59, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201 in healthy subjects.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Alzheimer's disease drug development pipeline: 2026.
Cummings JL, Zhou Y, Yang Y, Zhong K, et al · · 2026 · PMID 42095064 · DOI 10.1002/trc2.70251
Verify or expand the search:
- PubMed search for NCT06373094
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other Shanghai Synergy Pharmaceutical Sciences Co., Ltd. trials
Trials by the same sponsor.
- NCT05414734 — Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of HHT120 in Healthy Subjects · Phase 1 · withdrawn
- NCT03932916 — Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06373094 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
- Last refreshed: 18 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06373094.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing